Resolving intra-tumor heterogeneity and clonal evolution of core-binding factor acute myeloid leukemia patients with single-cell resolution [0.03%]
采用单细胞分辨率解析核心结合因子急性髓系白血病患者的肿瘤异质性和克隆进化
Raphael Hablesreiter,Paulina M Strzelecka,Klara Kopp et al.
Raphael Hablesreiter et al.
Reconstructing and understanding intra-tumor heterogeneity, the coexistence of multiple genetically distinct subclones within the tumor of a patient, and tumor development is essential for resolving carcinogenesis and for identifying mechan...
Lactate and lactylation in cancer: drivers of immune suppression and microenvironmental reprogramming [0.03%]
乳酸和乳酸化在癌症中的作用：免疫抑制和微环境重塑的驱动因素
Xiaoyu Ji,Limin Xia
Xiaoyu Ji
Lactate, a key metabolite of the Warburg effect, plays a central role in shaping multiple hallmarks of cancer. Through lactate shuttling and engagement with specific receptors, it activates downstream signaling pathways that remodel the tum...
Chimeric antigen receptor modified hematopoietic stem cells (CAR-HSCs) arm all immune forces for anti-tumor in mice [0.03%]
嵌合抗原受体修饰的造血干细胞(CAR-HSCs)使小鼠所有免疫细胞发挥抗肿瘤作用
Tao Wang,Ping Liu,Dongliang Zhang et al.
Tao Wang et al.
Chimeric antigen receptor T cell (CAR-T) is the main salvage therapy for relapsed or refractory large B-cell lymphoma (r/r LBCL). However, over 50% of patients relapse after CAR-T therapy. In this work, we transduced the CAR gene into hemat...
Pitavastatin is a novel Mcl-1 inhibitor that overcomes paclitaxel resistance in triple-negative breast cancer [0.03%]
新型的Mcl-1抑制剂pitavastatin能够克服三阴性乳腺癌细胞对紫杉醇耐药性
Dongmi Ko,Soeun Park,Minsu Park et al.
Dongmi Ko et al.
Background: Triple-negative breast cancer (TNBC) is notorious for its poor prognosis, high metastatic rates, and resistance to chemotherapy. We sought to investigate the anticancer effects of pitavastatin (PITA), a promis...
Inhibition of EYA family tyrosine phosphatase activity reveals a therapeutic vulnerability and enhances Menin and DOT1L inhibitor efficacy in KMT2A-rearranged leukemia [0.03%]
EYA家族酪氨酸磷酸酶活性抑制可揭示出治疗弱点并增强MENIN和DOT1L抑制剂在KMT2A重排白血病中的疗效
Lola Badmus,Nicholas J Achille,Shubin Zhang et al.
Lola Badmus et al.
MLL (KMT2A)-rearranged leukemia (MLL-r) is a highly aggressive hematologic malignancy driven by transcriptional dysregulation. Here, we identify EYA family phosphatase activity, particularly EYA1 and EYA3, as key vulnerabilities in MLL-r le...
KMT2A alterations in acute myeloid leukemia: a proposed genetic risk model and transplantation outcomes [0.03%]
急性髓系白血病中KMT2A基因改变的遗传风险模型及移植预后研究
Li Chen,Jianfeng Li,Yongmei Zhu et al.
Li Chen et al.
KMT2A-altered acute myeloid leukemia (AML) comprises rearrangements (KMT2A-r), partial tandem duplications (KMT2A-PTD), and dual alterations (KMT2A-r/PTD). In this study of 125 patients, these subgroups exhibited distinct molecular profiles...
Anti-tumor vaccine efficacy depends on adjuvant type and associates with induced IgG subclass and glycosylation profiles [0.03%]
抗肿瘤疫苗的效力取决于佐剂的类型并与诱导的IgG亚类和糖基化谱型相关
Selina Lehrian,Anna Wasynczuk,Janina Petry et al.
Selina Lehrian et al.
Vaccination with tumor-(neo) antigen plus adjuvant is emerging as a promising cancer-therapy. However, as different adjuvants induce distinct immune cell and antibody (Ab) responses, selecting the right adjuvants remains challenging. Here, ...
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma [0.03%]
靶向BCMA的CAR-T细胞疗法Zevo-cilta-cel治疗复发/难治多发性骨髓瘤II期临床试验
Wenming Chen,Chengcheng Fu,Baijun Fang et al.
Wenming Chen et al.
Background: Zevorcabtagene autoleucel (zevor-cel) is a fully human autologous CAR T-cell therapy targeting B-cell maturation antigen approved in China since 2024 for patients with relapsed/refractory multiple myeloma (RRM...
Brain metastasis-associated cancer fibroblasts drive tumor progression and therapeutic resistance through IL26 and CX3CL1 signaling in non-small-cell lung cancer [0.03%]
非小细胞肺癌相关脑转移癌纤维母细胞通过IL26和CX3CL1信号促进肿瘤进展及治疗抵抗
S M Abdus Salam,Eshrat Jahan,Eun-Jung Ahn et al.
S M Abdus Salam et al.
Brain metastases (BM) from non-small cell lung cancer (NSCLC) represent a significant clinical challenge, characterized by poor prognosis and treatment resistance. While cancer-associated fibroblasts (CAFs) are recognized as crucial compone...
Revisiting thrombophilia testing: leveraging next-generation sequencing for precision in VTE management [0.03%]
重温血栓病检测：利用下一代测序技术提高静脉血栓栓塞管理的精准性
Ilham Youssry,Nardeen Ayad
Ilham Youssry
Venous thromboembolism (VTE) remains a significant cause of morbidity and mortality, particularly among individuals with inherited thrombophilia. Despite the widespread use of thrombophilia testing, its clinical value is often questioned du...